PDCD1 and head and neck squamous cell carcinoma: Clinical evidence demonstrates that these ICIs have contributed to a partial improvement in patient survival rates.[21, 22] However, the efficacy of anti‐PD‐1 monotherapy remains limited in advanced and metastatic HNSCC patients.